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A B S T R A C T
Objectives: In Fiji, autochthonous chikungunya virus (CHIKV) infection was ﬁrst detected in March 2015.
In a previous serosurvey conducted during October–November 2015, we reported a prevalence of
anti-CHIKV IgG antibodies of 0.9%. In the present study, we investigated the seroprevalence of CHIKV
two years after its emergence in Fiji.
Methods: Sera from 320 residents of Fiji recruited in June 2017, from the same cohort of individuals that
participated in the serosurvey in 2015, were tested for the presence of IgG antibodies against CHIKV using
a recombinant antigen-based microsphere immunoassay.
Results: Between 2015 and 2017, CHIKV seroprevalence among residents increased from 0.9% (3/333) to
12.8% (41/320). Of the participants with available serum samples collected in both 2015 and 2017
(n = 200), 31 (15.5%) who were seronegative in 2015 had seroconverted to CHIKV in 2017.
Conclusions: Our ﬁndings suggest that low-level transmission of CHIKV occurred during the two years
following the emergence of thevirusinFiji. NoCHIKV infectionhasbeenreported inFiji since2017,but dueto
the presumed low herd immunity of the population, the risk of CHIKV re-emergence is high. Consequently,
chikungunya should be considered in the differential diagnosis of acute febrile diseases in Fiji.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Introduction
Chikungunya virus (CHIKV, Alphavirus genus, Togaviridae
family) is transmitted to humans by Aedes mosquitoes. CHIKV
infection causes an acute febrile illness commonly with poly-
arthralgia which can become chronic, maculopapular rash,
headache, fatigue and myalgia (Ministry of Health and Medical
Services, 2015). In Fiji (884,887 inhabitants in 2017), the ﬁrst
reported CHIKV infection was detected in March 2015 (Ministry of
Health and Medical Services, 2015). Four autochthonous CHIKV
infections were subsequently detected the same year, followed by
86 in 2016, and 2 in 2017 (Kama et al., 2019). During this period,
CHIKV infection was also reported in travelers returning from Fiji
to Australia and New Zealand (The Australian Government
Department of Health, 2019; Institute of Environmental Science
and Research Limited, 2018). A serosurvey conducted during
October-November 2015 in the Central Division, where 43% of the
Fiji population is living, showed a prevalence of anti-CHIKV
immunoglobulin class G (IgG) antibodies of 0.9% (Kama et al.,
2019). In the present study, we investigated the seroprevalence of
CHIKV in the same population two years after emergence in Fiji.
Methods
Our study was conducted in 320 volunteers with no signiﬁcant
acute illness recruited in the Central Division in June 2017, from the
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same cohort previously tested in 2015 (Kama et al., 2019). All
blood samples were tested for the presence of IgG against CHIKV
using the same recombinant antigen-based microsphere immu-
noassay (MIA) as in the serosurvey conducted in 2015 (Kama
et al., 2019), with 100% sensitivity and speciﬁcity. Samples were
also tested by MIA for IgG against Ross River virus (RRV), a related
alphavirus that caused a large outbreak in Fiji in 1979 and has since
established endemic circulation, as suggested by recent evidence
(Aubry et al., 2019). A subset of paired serum samples collected in
2015 and 2017 was also tested for the presence of neutralizing
antibodies against CHIKV as previously described (Aubry et al.,
2018). Data were analyzed with GraphPad Prism 6.03 using the
Fisher’s exact test.
Results
The prevalence of anti-CHIKV IgG in the participants from the
Central Division increased from 0.9% (95%CI 0.2%–2.6%) in 2015 to
12.8% (95%CI 9.4%–17%) in 2017 (p < 0.0001) (Table 1). The
prevalence of anti-RRV IgG was stable over the same period, with
37.2% (95%CI 32.4%–42.7%) in 2015 and 39.1% (95%CI 33.7%–44.7%)
in 2017 (p = 0.687). Among the 200 participants with available
serum samples collected in both 2015 and 2017, 31 (15.5%; 95%CI
10.8%–21.3%) participants who had no detectable anti-CHIKV IgG
and 16 (8%; 95%CI 4.6%–12.7%) with no anti-RRV IgG in 2015 had
seroconverted to these respective viruses by 2017 (Table 2). Among
the 31 participants with anti-CHIKV IgG in 2017, 5 (16.1%; 95%CI
5.5%–33.7%) had anti-RRV IgG in 2015. Moreover, for all 31
participants that were found seronegative in 2015 and subse-
quently tested seropositive in 2017 against CHIKV by MIA, paired
serum samples were also tested by neutralization assay and results
were 100% concordant between the two assays.
Discussion
Although CHIKV was introduced to an immunologically naïve
population in Fiji, as demonstrated by a CHIKV seroprevalence <1%
in 2015 (Kama et al., 2019), our serological ﬁndings show the
transmission rate in the following two years was relatively low,
with seroprevalence of 12.8% in 2017. This result contrasts with the
explosive CHIKV outbreak that occurred in 2014–2015 in French
Polynesia (Aubry et al., 2015), another Paciﬁc island country, where
a seroprevalence of 76% was found one year after the emergence of
the virus (Aubry et al., 2018). A possible explanation for the large
difference in transmission between the two countries is that recent
exposure to RRV may provide cross-protection against CHIKV
infection. Indeed, higher RRV seroprevalence was detected in the
general population from Fiji (37.2% in 2015 and 39.1% in 2017)
compared to French Polynesia (18% in 2015) (Aubry et al., 2019;
Aubry et al., 2017). Moreover, the ﬁnding that 8% of Fiji residents
who were initially seronegative to RRV had seroconverted between
2015 and 2017 suggests recent circulation of the virus in Fiji,
whereas in French Polynesia the low RRV seroprevalence (1%) in
children aged less than 16 years in 2014 (Aubry et al., 2017)
suggests limited transmission during the past two decades. This
hypothesis is further supported by experiments showing that mice
infected with RRV and challenged with CHIKV 4.5 months later had
signiﬁcantly reduced CHIKV viremia and were protected against
the disease (Gardner et al., 2010). Another factor that may have
limited circulation of CHIKV in Fiji is possible competition for
transmission by the mosquito host (Vogels et al., 2019), as CHIKV
circulated concurrently with other arboviruses (Zika virus, dengue
viruses and RRV) that share the same mosquito vectors (Kama
et al., 2019; Aubry et al., 2019) Additional studies are therefore
needed to identify the factors modulating concurrent transmission
of multiple mosquito-borne viruses in Fiji.
In our study, participants were recruited in the Central Division,
where 74.2% (69/93) of the conﬁrmed cases of CHIKV infection
in Fiji were detected between 2015–2017. Serological evidence
together with surveillance data (Kama et al., 2019) strongly suggest
low CHIKV transmission in Fiji between 2015–2017. Since most
residents in Fiji are still susceptible to CHIKV, there is a high risk of
reemergence in the coming years. Consequently, active surveil-
lance is crucial for early detection of new cases of CHIKV infection,
and chikungunya should be considered in the differential diagnosis
of acute febrile illness in Fiji, particularly in the presence of
polyarthralgia and/or rash.
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Table 1
Prevalence of anti-chikungunya virus and anti-Ross River virus antibodies in a representative subset of the Fijian population sampled in the Central Division during October-
November 2015 (N = 333) and June 2017 (N = 320).
Sampling period Age range (median), y N No. positive (% [95% CI])
CHIKV RRV
October–November,
2015
4–80 (29) 333 3 (0.9 [0.2–2.6]) 124 (37.2 [32.4–42.7])
June, 2017 6–84 (29) 320 41 (12.8 [9.4–17]) 125 (39.1 [33.7–44.7])
CHIKV, chikungunya virus; RRV, Ross River virus.
Table 2
Positivity for anti-chikungunya virus and anti-Ross River virus antibodies in paired
serum samples serially collected from the same participants (N = 200) during
October-November 2015 and June 2017.
2015 2017
CHIKV+ CHIKV RRV+ RRV
CHIKV+ 0 2 ‒ ‒
CHIKV 31 167 ‒ ‒
RRV+ ‒ ‒ 56 12
RRV ‒ ‒ 16 116
CHIKV, chikungunya virus; RRV, Ross River virus.
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